Human colorectal cancer organoids were treated with the TROP2-targeting antibody-drug conjugate Sacituzumab Govitecan (SG) or non-targeting control IgG1-SN-38. Samples were harvested at different time points under treatment {0h, 3h, 6h, 9h, 12h} as well as after drug washout at 12 h on the following...
ORGANISM(S): Homo sapiens
